Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07831824 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])(SPARROW) | recruiting | Phase 2 / Phase 3 | 408 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04053842 | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy(IGPC-5) | completed | Phase 2 | 16 | Glenn BaumanOTHER | 1 | Sep 18, 2026 |
| clinicaltrials |
| NCT04985565 | Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer | active not recruiting | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05958082 | Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer | active not recruiting | N/A | 50 | Henry Ford Health SystemOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06085729 | Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06678126 | Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP) | recruiting | Phase 2 | 104 | Scott TyldesleyOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation(EvoPAR-PR02) | recruiting | Phase 3 | 700 | AstraZenecaINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT07174063 | A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer | active not recruiting | Phase 1 | 6 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 736 | BioNTech SEINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT07497919 | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07548164 | Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer | recruiting | Phase 3 | 224 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07650240 | Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial(SPARKLE) | recruiting | Phase 2 | 202 | Mayo ClinicOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07829068 | Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy(INTROSPECT) | active not recruiting | N/A | 30 | University Hospital, GenevaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02415621 | Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer | completed | Early Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)(PREPARE) | completed | N/A | 792 | Institut BergoniéOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04556045 | Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer | completed | N/A | 21 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05003752 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer(Hypo-Combi) | active not recruiting | Phase 1 / Phase 2 | 40 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05011188 | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Rahul AggarwalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05011383 | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers(VA-BAT) | recruiting | Phase 2 | 51 | VA Office of Research and DevelopmentFED | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05155046 | 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05616650 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05665738 | Two-fraction HDR Monotherapy for Localized Prostate Cancer | recruiting | N/A | 17 | University of California, San FranciscoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05705921 | Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer | active not recruiting | N/A | 484 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06284304 | A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL(DESTINATION) | completed | N/A | 20 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06568094 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06582446 | Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)(HypoElect) | recruiting | Phase 2 | 30 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | recruiting | Phase 3 | 1,440 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 17, 2026 | clinicaltrials |
| NCT07666217 | CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy(CoSMAP) | active not recruiting | — | 625 | Intuitive SurgicalINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07691697 | PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer(PSMA-OLIGO-PRO) | recruiting | — | 1,000 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07813637 | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC(PSMA-013-001) | recruiting | Phase 1 | 110 | Janux TherapeuticsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826858 | SPECTRA: Intraoperative Hyperspectral Imaging for Prostate Cancer(SPECTRA) | recruiting | N/A | 26 | Massimo ValerioOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01834001 | Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy | recruiting | — | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04808427 | Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer | suspended | N/A | 21 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06080113 | Cancer of the Prostate Treated With Focal Implantation of a RadioactivE Source(CAPFIRE) | enrolling by invitation | N/A | 50 | Herlev HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06380738 | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)(PROceed) | active not recruiting | — | 111 | AstraZenecaINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07549256 | Cannabidiol for Pain Relief of Patients With End-stage mCRPC(ProCan) | recruiting | Phase 2 | 58 | Regionshospital NordjyllandOTHER_GOV | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07608718 | Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 2 | 19 | Pedro Barata, MD, MScOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02522715 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03697148 | Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer | active not recruiting | N/A | 852 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04995198 | PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness | recruiting | — | 500 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05670106 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05712473 | An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer | active not recruiting | — | 500 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05751941 | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06150417 | MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) | recruiting | Phase 2 | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials